NCT00551694 is a Phase 1 clinical trial of GSK256073A tablets in Healthy Subjects, sponsored by GlaxoSmithKline.

Who is sponsoring NCT00551694?

NCT00551694 is sponsored by GlaxoSmithKline.

What drugs are being tested in NCT00551694?

Interventions in NCT00551694: GSK256073A tablets.

What condition does NCT00551694 study?

NCT00551694 studies Healthy Subjects, Dyslipidaemias.

Is NCT00551694 still recruiting?

NCT00551694 is currently completed. Last updated 31 May 2012.

Last reviewed 2012-05-31 · How we verify

NCT00551694

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Second Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single and a Repeat Oral Dose of GSK256073A in Healthy Adult Subjects

Completed Phase 1 Last updated 31 May 2012

What this trial tests

Phase 1 trial testing GSK256073A tablets in Healthy Subjects in 4 participants. Completed in 1 December 2007.

Timeline

1 October 2007

Primary endpoint
1 December 2007

1 December 2007

Quick facts

Lead sponsor	GlaxoSmithKline
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	4
Start date	1 October 2007
Primary completion	1 December 2007
Estimated completion	1 December 2007
Sites	1 location across United States

Drugs / interventions tested

GSK256073A tablets — full drug profile →

Conditions studied

Healthy Subjects — all drugs for Healthy Subjects →
Dyslipidaemias — all drugs for Dyslipidaemias →

Sponsor

GlaxoSmithKline — full company profile →

Who can join

Adults 18 to 55, any sex, with Healthy Subjects or Dyslipidaemias. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

AEs, 12-Lead ECG, vital signs, nursing/physician observation, safety lab tests, flushing throughout the study.
Time frame: throughout the study.
AUC and Cmax
Time frame: throughout the study
Measures of accumulation ratios throughout the study (Ro, Rp, and Rs)[Period 2]
Time frame: throughout the study

Sponsor's own description

The purpose of this study is to compare the effects of single and repeat doses of GSK256073 with placebo in HVT subjects that have been administrated GSK256073 in the HMA107787 study

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

GPCRs involved in metabolic diseases: pharmacotherapeutic development updates.
Jin C, Chen H, Xie L, Zhou Y, et al · · 2024 · cited 25× · PMID 38326623 · DOI 10.1038/s41401-023-01215-2

Verify or expand the search:

Other recruiting trials for Healthy Subjects

Currently open trials in the same condition.

NCT07222020 — Phase 1 Study of Intravaginal KB15A · Phase 1 · recruiting
NCT07350538 — The Critical Link Between Gut Microbiome Dysfunction, Cravings and Relapse: RECLAIM-GUT TRIAL · NA · active not recruiting
NCT07304791 — This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and P · Phase 1 · recruiting
NCT07059858 — Bladder and Bowel Functions, Participation and Quality of Life in Children With Intellectual Disabilities · recruiting
NCT07331389 — A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin · Phase 1 · recruiting

Other GlaxoSmithKline trials

Trials by the same sponsor.

NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose · Phase 1 · not yet recruiting
NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00551694 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
Last refreshed: 31 May 2012

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00551694.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing